BI's Pradaxa antidote progresses

Share this article:

Boehringer Ingelheim has inched closer to a Pradaxa antidote. The company announced Wednesday that it is set to launch its first-ever test among patients. The blood drug antidote, called idarucizumab, has been tested in healthy patients, and this latest test will involve emergency rooms in 35 countries.

Lack of an antidote is a concern with oral anti-coagulants, which include BI's Pradaxa as well as the BMS/Pfizer treatment Eliquis and Janssen's Xarelto. There is one exception: standby warfarin which, as MedPage's editor-in-chief noted in an April piece, is reversible.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters